Cardiomyocyte-specific ablation of CD36 accelerates the progression from compensated cardiac hypertrophy to heart failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 312, Issue 3, 2017, Pages H552-H560

  Sung, Miranda M ^a   Byrne, Nikole J ^a   Kim, Ty T ^a   Levasseur, Jody ^a   Masson, Grant ^a   Boisvenue, Jamie J ^a   Febbraio, Maria ^a   Dyck, Jason R B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

CD36; Fatty acid metabolism; Heart failure; Hypertrophy; Pressure overload

Indexed keywords

ADENOSINE TRIPHOSPHATE; CD36 ANTIGEN; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; TAMOXIFEN; ANTIESTROGEN; TRIACYLGLYCEROL;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA SURGERY; ARTICLE; CARDIAC MUSCLE CELL; COMPENSATED CARDIAC HYPERTROPHY; CONTROLLED STUDY; DIET; DISEASE COURSE; ENERGY METABOLISM; ENERGY RESOURCE; ENERGY TRANSFER; FATTY ACID OXIDATION; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRESS; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CARDIAC MUSCLE; CARDIOMEGALY; CHEMICALLY INDUCED; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ADENOSINE TRIPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIGENS, CD36; CARDIOMEGALY; DISEASE PROGRESSION; ENERGY METABOLISM; ESTROGEN ANTAGONISTS; HEART FAILURE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; MYOCYTES, CARDIAC; TAMOXIFEN; TRIGLYCERIDES;

EID: 85015308242     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00626.2016     Document Type: Article

References (30)

1. Akki A, Seymour AM. Western diet impairs metabolic remodelling and contractile efficiency in cardiac hypertrophy. Cardiovasc Res 81: 610-617, 2009. doi:10.1093/cvr/cvn316.
2. Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, Sejlitz T, Escher E, Silverstein RL, Lamontagne D, Ong H. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res 90: 844-849, 2002. doi:10.1161/01.RES.0000016164.02525.B4.
3. Bonen A, Han XX, Tandon NN, Glatz JF, Lally J, Snook LA, Luiken JJ. FAT/CD36 expression is not ablated in spontaneously hypertensive rats. J Lipid Res 50: 740-748, 2009. doi:10.1194/jlr.M800237-JLR200.
4. Chou IP, Chiu YP, Ding ST, Liu BH, Lin YY, Chen CY. Adiponectin receptor 1 overexpression reduces lipid accumulation and hypertrophy in the heart of diet-induced obese mice—possible involvement of oxidative stress and autophagy. Endocr Res 39: 173-179, 2014. doi:10.3109/ 07435800.2013.879165.
5. Dobrzyn P, Pyrkowska A, Duda MK, Bednarski T, Maczewski M, Langfort J, Dobrzyn A. Expression of lipogenic genes is upregulated in the heart with exercise training-induced but not pressure overload-induced left ventricular hypertrophy. Am J Physiol Endocrinol Metab 304: E1348-E1358, 2013. doi:10.1152/ajpendo.00603.2012.
6. Dolinsky VW, Chakrabarti S, Pereira TJ, Oka T, Levasseur J, Beker D, Zordoky BN, Morton JS, Nagendran J, Lopaschuk GD, Davidge ST, Dyck JR. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim Biophys Acta 1832: 1723-1733, 2013. doi:10.1016/j.bbadis.2013.05.018.
7. Dolinsky VW, Rogan KJ, Sung MM, Zordoky BN, Haykowsky MJ, Young ME, Jones LW, Dyck JR. Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice. Am J Physiol Endocrinol Metab 305: E243-E253, 2013. doi:10.1152/ajpendo. 00044.2013.
8. Fillmore N, Mori J, Lopaschuk GD. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br J Pharmacol 171: 2080-2090, 2014. doi:10.1111/bph. 12475.
9. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497-509, 1957.
10. Gutierrez JA, Karwatowska-Prokopczuk E, Murphy SA, Belardinelli L, Farzaneh-Far R, Walker G, Morrow DA, Scirica BM. Effects of ranolazine in patients with chronic angina in patients with and without percutaneous coronary intervention for acute coronary syndrome: Observations from the MERLIN-TIMI 36 trial. Clin Cardiol 38: 469-475, 2015. doi:10.1002/clc.22425.
11. Hajri T, Ibrahimi A, Coburn CT, Knapp FF Jr, Kurtz T, Pravenec M, Abumrad NA. Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J Biol Chem 276: 23661-23666, 2001. doi:10.1074/jbc.M100942200.
12. Heather LC, Howell NJ, Emmanuel Y, Cole MA, Frenneaux MP, Pagano D, Clarke K. Changes in cardiac substrate transporters and metabolic proteins mirror the metabolic shift in patients with aortic stenosis. PLoS One 6: e26326, 2011. doi:10.1371/journal.pone.0026326.
13. Heather LC, Pates KM, Atherton HJ, Cole MA, Ball DR, Evans RD, Glatz JF, Luiken JJ, Griffin JL, Clarke K. Differential translocation of the fatty acid transporter, FAT/CD36, and the glucose transporter, GLUT4, coordinates changes in cardiac substrate metabolism during ischemia and reperfusion. Circ Heart Fail 6: 1058-1066, 2013. doi:10.1161/CIRCHEARTFAILURE.112.000342.
14. Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD. Targeting fatty acid and carbohydrate oxidation---a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 1813: 1333-1350, 2011. doi:10.1016/j.bbamcr.2011.01.015.
15. Kienesberger PC, Pulinilkunnil T, Sung MM, Nagendran J, Haemmerle G, Kershaw EE, Young ME, Light PE, Oudit GY, Zechner R, Dyck JR. Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction. Mol Cell Biol 32: 740-750, 2012. doi:10.1128/ MCB.06470-11.
16. Koonen DP, Febbraio M, Bonnet S, Nagendran J, Young ME, Michelakis ED, Dyck JR. CD36 expression contributes to age-induced cardiomyopathy in mice. Circulation 116: 2139-2147, 2007. doi:10.1161/ CIRCULATIONAHA.107.712901.
17. Koonen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong H, Vance DE, Dyck JR. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes 56: 2863-2871, 2007. doi:10.2337/db07-0907.
18. Kuang M, Febbraio M, Wagg C, Lopaschuk GD, Dyck JR. Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia. Circulation 109: 1550-1557, 2004. doi:10.1161/01.CIR.0000121730.41801.12.
19. Lauzier B, Merlen C, Vaillant F, McDuff J, Bouchard B, Beguin PC, Dolinsky VW, Foisy S, Villeneuve LR, Labarthe F, Dyck JR, Allen BG, Charron G, Des Rosiers C. Post-translational modifications, a key process in CD36 function: Lessons from the spontaneously hypertensive rat heart. J Mol Cell Cardiol 51: 99-108, 2011. doi:10.1016/j.yjmcc.2011. 04.001.
20. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 90: 207-258, 2010. doi:10.1152/physrev.00015.2009.
21. Nagendran J, Pulinilkunnil T, Kienesberger PC, Sung MM, Fung D, Febbraio M, Dyck JR. Cardiomyocyte-specific ablation of CD36 improves post-ischemic functional recovery. J Mol Cell Cardiol 63: 180-188, 2013. doi:10.1016/j.yjmcc.2013.07.020.
22. Neglia D, De Caterina A, Marraccini P, Natali A, Ciardetti M, Vecoli C, Gastaldelli A, Ciociaro D, Pellegrini P, Testa R, Menichetti L, L’Abbate A, Stanley WC, Recchia FA. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 293: H3270-H3278, 2007. doi:10.1152/ajpheart.00887.2007.
23. Peng S, Zhao M, Wan J, Fang Q, Fang D, Li K. The efficacy of trimetazidine on stable angina pectoris: A meta-analysis of randomized clinical trials. Int J Cardiol 177: 780-785, 2014. doi:10.1016/j.ijcard. 2014.10.149.
24. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2: re3, 2009. doi:10.1126/scisignal.272re3.
25. Steinbusch LK, Luiken JJ, Vlasblom R, Chabowski A, Hoebers NT, Coumans WA, Vroegrijk IO, Voshol PJ, Ouwens DM, Glatz JF, Diamant M. Absence of fatty acid transporter CD36 protects against Western-type diet-related cardiac dysfunction following pressure overload in mice. Am J Physiol Endocrinol Metab 301: E618-E627, 2011. doi:10.1152/ajpendo.00106.2011.
26. Sung MM, Das SK, Levasseur J, Byrne NJ, Fung D, Kim TT, Masson G, Boisvenue J, Soltys CL, Oudit GY, Dyck JR. Resveratrol treatment of mice with pressure-overload-induced heart failure improves diastolic function and cardiac energy metabolism. Circ Heart Fail 8: 128-137, 2015. doi:10.1161/CIRCHEARTFAILURE.114.001677.
27. Sung MM, Koonen DP, Soltys CL, Jacobs RL, Febbraio M, Dyck JR. Increased CD36 expression in middle-aged mice contributes to obesityrelated cardiac hypertrophy in the absence of cardiac dysfunction. J Mol Med (Berl) 89: 459-469, 2011. doi:10.1007/s00109-010-0720-4.
28. Sung MM, Zordoky BN, Bujak AL, Lally JS, Fung D, Young ME, Horman S, Miller EJ, Light PE, Kemp BE, Steinberg GR, Dyck JR. AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism. Cardiovasc Res 107: 235-245, 2015. doi:10.1093/cvr/cvv166.
29. Zhabyeyev P, Gandhi M, Mori J, Basu R, Kassiri Z, Clanachan A, Lopaschuk GD, Oudit GY. Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload. Cardiovasc Res 97: 676-685, 2013. doi:10.1093/cvr/cvs424.
30. Zhang Y, Bao M, Dai M, Wang X, He W, Tan T, Lin D, Wang W, Wen Y, Zhang R. Cardiospecific CD36 suppression by lentivirus-mediated RNA interference prevents cardiac hypertrophy and systolic dysfunction in high-fat-diet induced obese mice. Cardiovasc Diabetol 14: 69, 2015. doi:10.1186/s12933-015-0234-z.